Overview
Primary IGF-I Deficiency (SPIGFD), also known as type I primary IGF-1 deficiency, is a rare genetic disorder characterized by severe growth impairment and multiple clinical manifestations beyond short stature. This condition arises from impaired signaling through the insulin-like growth factor 1 (IGF-1) pathway, leading to growth failure and a constellation of physical abnormalities. The rarity and variability in diagnostic criteria contribute to diagnostic challenges, necessitating a high index of suspicion for accurate identification. Early recognition and intervention are crucial for optimizing growth outcomes and managing associated complications [PMID:40626687].
Epidemiology
SPIGFD is recognized as a rare disease with an estimated prevalence ranging from 1 in 40,000 to 1 in 100,000 live births, though this can vary due to inconsistent diagnostic criteria and differences in growth charts across international populations. The variability in diagnostic approaches and the subtlety of clinical presentations often delay diagnosis, sometimes until adulthood. Genetic studies have identified mutations in genes involved in the IGF-1 signaling pathway, such as IGF1R and IGFALS, as underlying causes, highlighting the heterogeneous nature of the disorder [PMID:40626687]. In clinical practice, awareness of these genetic underpinnings is essential for timely genetic counseling and family screening.
Clinical Presentation
Patients with SPIGFD typically present with a distinctive phenotype characterized by extreme short stature, often defined by a height standard deviation score (HtSDS) ≤ −3. This profound growth retardation is accompanied by a range of other clinical features that extend beyond mere physical stature. Neonatal hypoglycemia is a common early finding, reflecting the metabolic challenges associated with GH insensitivity. Midfacial hypoplasia, small genitalia, and delayed puberty are frequently observed, contributing to the complex clinical picture. Additionally, patients may exhibit other physical abnormalities such as delayed bone age, dental anomalies, and mild intellectual disability in some cases [PMID:40626687]. These multifaceted presentations underscore the importance of a comprehensive clinical evaluation to identify and manage the diverse aspects of the condition.
Diagnosis
Diagnosing SPIGFD involves a combination of clinical assessment and laboratory investigations. The cornerstone of diagnosis is the identification of low IGF-1 levels, typically below the 2.5th percentile for age and sex, in conjunction with normal or elevated growth hormone (GH) levels, which indicate GH insensitivity. This biochemical profile is critical for distinguishing SPIGFD from other forms of growth disorders where IGF-1 levels might be affected by different mechanisms. Additional supportive tests may include measurement of IGF-binding proteins, GH stimulation tests, and genetic testing to identify specific mutations in relevant genes. These diagnostic criteria help differentiate SPIGFD from other causes of short stature, ensuring appropriate management strategies are implemented [PMID:40626687]. Early and accurate diagnosis is pivotal for initiating timely therapeutic interventions that can significantly impact growth outcomes.
Management
The primary therapeutic approach for managing SPIGFD is recombinant human insulin-like growth factor 1 (rhIGF-1) therapy. This treatment has demonstrated substantial efficacy in improving growth outcomes. Studies have shown that rhIGF-1 therapy can increase height velocity to approximately 7.4 cm/year in the first year of treatment, leading to significant gains in HtSDS, with improvements of up to 1.9 units observed near adult height (NAH). The benefits of initiating rhIGF-1 therapy prepubertally are particularly pronounced, with treatment-naïve patients showing faster height gains compared to those treated during puberty or those previously on other growth therapies. Regular monitoring of growth parameters, metabolic status, and potential side effects such as hypoglycemia and intracranial hypertension, is essential to tailor treatment and ensure patient safety [PMID:40626687]. Multidisciplinary care involving endocrinologists, pediatricians, and geneticists is recommended to address the multifaceted needs of these patients comprehensively.
Prognosis & Follow-up
The prognosis for patients with SPIGFD significantly improves with early and sustained rhIGF-1 therapy, although achieving near-normal adult height remains challenging in many cases. Patients who begin rhIGF-1 treatment before puberty tend to achieve better height outcomes compared to those initiating therapy later. Long-term follow-up is crucial to monitor not only growth but also the development of associated complications, such as metabolic issues and psychological well-being. Regular assessments should include periodic evaluations of height, bone age, and overall health status to adjust treatment as necessary. Psychological support and counseling may also be beneficial, given the potential impact of chronic growth impairment on self-esteem and social development [PMID:40626687]. Continuous monitoring and adaptive management strategies are key to optimizing the quality of life for individuals with SPIGFD.
Key Recommendations
References
1 Ramon-Krauel M, Polak M, Maghnie M, Woelfle J, Sert C, Perrot V et al.. Near-Adult Height Outcomes in Patients Treated With rhIGF-1 for Severe Growth Failure: Real-World IGFD Registry Data. The Journal of clinical endocrinology and metabolism 2026. link
1 papers cited of 3 indexed.